20:43 , Jul 7, 2017 |  BC Week In Review  |  Company News

Opiant gets rights to Aegis' Intravail delivery tech

Addiction and eating disorder company Opiant Pharmaceuticals Inc. (OTCQB:OPNT) received rights to use the Intravail drug delivery system from Aegis Therapeutics LLC (San Diego, Calif.). The license covers all of Opiant's opioid antagonists. Opiant's OPNT002...
01:01 , Feb 25, 2017 |  BioCentury  |  Finance

Intranasal option

Canaan Partners sees a clear market opportunity for a non-invasive somatostatin analog, prompting the VC to lead a $25 million series A extension for Dauntless Pharmaceuticals Inc. The financing, announced Feb. 16, brings the round's...
00:57 , Feb 17, 2017 |  BC Extra  |  Financial News

Dauntless adds $25M to series A round

Dauntless Pharmaceuticals Inc. (San Diego, Calif.) raised $25 million in an extension of its series A round. New investor Canaan Partners joined existing investor Sofinnova Ventures in the round. The extension brings the round's total...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

Aegis Therapeutics, Dauntless Pharmaceuticals deal

Aegis granted Dauntless exclusive, worldwide rights to use its Intravail drug delivery technology with an undisclosed cancer compound. The deal includes an option for three additional products. Aegis said it received an upfront payment and...
07:00 , Jul 27, 2015 |  BioCentury  |  Finance

Gestalt of the times

Sofinnova Ventures is jumping on the asset-centric bandwagon with the creation of Dauntless Pharmaceuticals Inc. While the model has been around for a decade, Sofinnova decided to enter asset-centric investing after seeing that the whole...
01:24 , Jul 22, 2015 |  BC Extra  |  Financial News

Dauntless raises $12M series A

Asset-centric company Dauntless Pharmaceuticals Inc. (San Diego, Calif.) made its debut on Tuesday with a $12 million series A round from Sofinnova Ventures and a deal with drug delivery company Aegis Therapeutics LLC (San Diego,...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Company News

Aegis Therapeutics, Biodel deal

Aegis granted Biodel an exclusive, worldwide license to ProTek and Intravail technologies to develop and commercialize pharmaceutical formulations of glucagon. ProTek uses specific excipients as protein stabilizers in manufacturing processes and Intravail is a transmucosal...
07:00 , May 16, 2011 |  BC Week In Review  |  Company News

Aegis Therapeutics, Albany Medical College deal

Aegis and the college partnered to create an oral formulation of the college's breast cancer candidate AFPep using Aegis' Intravail transmucosal intranasal drug delivery technology. Aegis, which said it is in discussions with oncology pharma...
08:00 , Feb 1, 2010 |  BC Week In Review  |  Clinical News

Teriparatide: Phase I started

Zelos began a Phase I trial to compare an intranasal formulation of ZT-034 vs. injectable Forteo teriparatide for 7 days in 50 healthy postmenopausal women. Zelos developed the intranasal formulation using Intravail permeation enhancer technology...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Company News

Aegis Therapeutics, Roche deal

Roche received non-exclusive, worldwide rights to Aegis' ProTek protein stabilization technology. ProTek uses specific excipients as protein stabilizers in manufacturing processes and is in preclinical development for an undisclosed indication. Aegis will receive upfront fees...